{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:27:01Z","timestamp":1781184421284,"version":"3.54.1"},"reference-count":96,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR071653"],"award-info":[{"award-number":["R01AR071653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR19101"],"award-info":[{"award-number":["R01AR19101"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2020,10,1]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic therapy since the 1950s. Quinacrine, in particular, is used as an adjuvant therapy to other antimalarials for improved control of CLE. Quinacrine is currently unavailable in the USA, which has taken away an important component of the treatment regimen of patients with CLE. This paper reviews the evidence of available local and systemic therapies in order to assist providers in choosing alternative treatments for patients who previously benefited from quinacrine therapy.<\/jats:p>","DOI":"10.1136\/lupus-2020-000430","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T16:55:31Z","timestamp":1603212931000},"page":"e000430","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Candidate drug replacements for quinacrine in cutaneous lupus erythematosus"],"prefix":"10.1136","volume":"7","author":[{"given":"Daisy","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Dermatology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA"},{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-7095","authenticated-orcid":false,"given":"Robert","family":"Borucki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA"},{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Sontheimer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Utah School of Medicine, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA"},{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"2025091511540625000_7.1.e000430.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.008"},{"key":"2025091511540625000_7.1.e000430.2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-4362.1981.tb05295.x","article-title":"Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine","volume":"20","author":"Zuehlke","year":"1981","journal-title":"Int J Dermatol"},{"key":"2025091511540625000_7.1.e000430.3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2017.03.027","article-title":"The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis","volume":"77","author":"Mittal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00131.x"},{"key":"2025091511540625000_7.1.e000430.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067036","article-title":"TLR7\/TLR8 activation restores defective cytokine secretion by myeloid dendritic cells but not by plasmacytoid dendritic cells in HIV-infected pregnant women and newborns","volume":"8","author":"Cardoso","year":"2013","journal-title":"PLoS One"},{"key":"2025091511540625000_7.1.e000430.6","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jisp.2016.11.001","article-title":"Quinacrine Suppresses Tumor Necrosis Factor-\u03b1 and IFN-\u03b1 in Dermatomyositis and Cutaneous Lupus Erythematosus","volume":"18","author":"Alves","year":"2017","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2025091511540625000_7.1.e000430.7","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(89)90050-4"},{"key":"2025091511540625000_7.1.e000430.8","unstructured":"Rheumatology ACo . Quinacrine Shortage & What the ACR Is Doing about It, 2019. Available: https:\/\/www.the-rheumatologist.org\/article\/quinacrine-shortage-what-the-acr-is-doing-about-it\/ [Accessed 15 May 2020]."},{"key":"2025091511540625000_7.1.e000430.9","first-page":"s17","article-title":"The practice of compounding, associated compounding regulations, and the impact on dermatologists","volume":"17","author":"Quertermous","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"2025091511540625000_7.1.e000430.10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025091511540625000_7.1.e000430.11","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12018"},{"key":"2025091511540625000_7.1.e000430.12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/dth.12358","article-title":"Review of treatment for discoid lupus erythematosus","volume":"29","author":"Garza-Mayers","year":"2016","journal-title":"Dermatol Ther"},{"key":"2025091511540625000_7.1.e000430.13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2018.1646","article-title":"Decision tree model vs traditional measures to identify patterns of sun-protective behaviors and sun sensitivity associated with sunburn","volume":"154","author":"Morris","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025091511540625000_7.1.e000430.14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40257-015-0113-0","article-title":"Polypodium leucotomos: a potential new photoprotective agent","volume":"16","author":"Bhatia","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"2025091511540625000_7.1.e000430.15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0190-9622(03)02732-4","article-title":"Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin","volume":"50","author":"Middelkamp-Hup","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.16","first-page":"85","article-title":"Oral Polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses","volume":"146","author":"Caccialanza","year":"2011","journal-title":"G Ital Dermatol Venereol"},{"key":"2025091511540625000_7.1.e000430.17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaad.2010.09.773","article-title":"Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption","volume":"66","author":"Tanew","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.18","first-page":"183","article-title":"Subacute cutaneous lupus erythematosus: a case report of Polypodium leucotomos as an adjuvant therapy","volume":"89","author":"Breithaupt","year":"2012","journal-title":"Cutis"},{"key":"2025091511540625000_7.1.e000430.19","first-page":"19","article-title":"Safety and efficacy of oral Polypodium leucotomos extract in healthy adult subjects","volume":"8","author":"Nestor","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025091511540625000_7.1.e000430.20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/art.40018","article-title":"Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial","volume":"69","author":"Yokogawa","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025091511540625000_7.1.e000430.21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2014.12.025","article-title":"Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature","volume":"72","author":"Chasset","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.22","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.342"},{"key":"2025091511540625000_7.1.e000430.23","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314559630"},{"key":"2025091511540625000_7.1.e000430.24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjd.13006","article-title":"Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database","volume":"171","author":"Kuhn","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025091511540625000_7.1.e000430.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202322"},{"key":"2025091511540625000_7.1.e000430.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150379"},{"key":"2025091511540625000_7.1.e000430.27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaad.2017.08.045","article-title":"Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","article-title":"Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study","volume":"78","author":"Mittal","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.29","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.191"},{"key":"2025091511540625000_7.1.e000430.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"2025091511540625000_7.1.e000430.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.064"},{"key":"2025091511540625000_7.1.e000430.32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2019.07.027","article-title":"An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review","volume":"82","author":"Shipman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.044"},{"key":"2025091511540625000_7.1.e000430.34","doi-asserted-by":"crossref","DOI":"10.5070\/D31XH7Z688","article-title":"Treatment of cutaneous lupus with Elidel","volume":"8","author":"Zabawski","year":"2002","journal-title":"Dermatol Online J"},{"key":"2025091511540625000_7.1.e000430.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03138.x"},{"key":"2025091511540625000_7.1.e000430.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.03.037"},{"key":"2025091511540625000_7.1.e000430.37","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamadermatol.2015.1349","article-title":"Treatment of scarring alopecia in discoid variant of chronic cutaneous lupus erythematosus with tacrolimus lotion, 0.3","volume":"151","author":"Milam","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025091511540625000_7.1.e000430.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03351.x"},{"key":"2025091511540625000_7.1.e000430.39","unstructured":"CJ S , MI C , RD S , et al . Fitzpatrick's dermatology, 9e. In: S K , A M , AL B , et al , eds. New York, NY: McGraw-Hill, 2019."},{"key":"2025091511540625000_7.1.e000430.40","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1986.01660140060018"},{"key":"2025091511540625000_7.1.e000430.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb14851.x"},{"key":"2025091511540625000_7.1.e000430.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1981.tb01711.x"},{"key":"2025091511540625000_7.1.e000430.43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000249338","article-title":"Dapsone in the treatment of cutaneous lupus erythematosus","volume":"172","author":"Lindskov","year":"1986","journal-title":"Dermatology"},{"key":"2025091511540625000_7.1.e000430.44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000441054","article-title":"Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature","volume":"232","author":"Klebes","year":"2016","journal-title":"Dermatology"},{"key":"2025091511540625000_7.1.e000430.45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.det.2010.03.014","article-title":"Innovative use of dapsone","volume":"28","author":"Wozel","year":"2010","journal-title":"Dermatol Clin"},{"key":"2025091511540625000_7.1.e000430.46","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2018.02.049","article-title":"Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: a multicenter retrospective study","volume":"79","author":"Cesbron","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.48","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaad.2016.01.054","article-title":"Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients","volume":"74","author":"Fennira","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.007"},{"key":"2025091511540625000_7.1.e000430.50","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1186\/ar4111","article-title":"Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus","volume":"14","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2025091511540625000_7.1.e000430.51","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13226"},{"key":"2025091511540625000_7.1.e000430.52","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670280071013"},{"key":"2025091511540625000_7.1.e000430.53","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-4362.1996.tb00657.x","article-title":"Efficacy of sulfasalazine in discoid lupus erythematosus","volume":"35","author":"Art\u00fcz","year":"1996","journal-title":"Int J Dermatol"},{"key":"2025091511540625000_7.1.e000430.54","first-page":"151","article-title":"[Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases]","volume":"124","author":"Delaporte","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"2025091511540625000_7.1.e000430.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605163342002"},{"key":"2025091511540625000_7.1.e000430.56","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/imj.12896","article-title":"Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis","volume":"45","author":"Cummins","year":"2015","journal-title":"Intern Med J"},{"key":"2025091511540625000_7.1.e000430.57","doi-asserted-by":"publisher","DOI":"10.3109\/03009749309099254"},{"key":"2025091511540625000_7.1.e000430.58","doi-asserted-by":"crossref","DOI":"10.5070\/D35359197S","article-title":"Vesico-bullous subacute cutaneous lupus erythematosus--an uncommon entity successfully treated with dapsone and hydroxychloroquine","volume":"18","author":"Pinto-Almeida","year":"2012","journal-title":"Dermatol Online J"},{"key":"2025091511540625000_7.1.e000430.59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb02726.x"},{"key":"2025091511540625000_7.1.e000430.60","doi-asserted-by":"publisher","DOI":"10.1007\/s002960050058"},{"key":"2025091511540625000_7.1.e000430.61","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.114608"},{"key":"2025091511540625000_7.1.e000430.62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06552.x"},{"key":"2025091511540625000_7.1.e000430.63","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.214"},{"key":"2025091511540625000_7.1.e000430.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010193431604"},{"key":"2025091511540625000_7.1.e000430.65","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04875.x"},{"key":"2025091511540625000_7.1.e000430.66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07826.x"},{"key":"2025091511540625000_7.1.e000430.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.08.011"},{"key":"2025091511540625000_7.1.e000430.68","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1985.01660100103026"},{"key":"2025091511540625000_7.1.e000430.69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0190-9622(88)70259-5","article-title":"Resistant discoid lupus erythematosus of palms and Soles: successful treatment with azathioprine","volume":"19","author":"Ashinoff","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"2025091511540625000_7.1.e000430.70","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1986.01660190022004"},{"key":"2025091511540625000_7.1.e000430.71","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.04510010083008"},{"key":"2025091511540625000_7.1.e000430.72","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu1067sr"},{"key":"2025091511540625000_7.1.e000430.73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-4632.2007.03333.x","article-title":"Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin","volume":"47","author":"Suess","year":"2008","journal-title":"Int J Dermatol"},{"key":"2025091511540625000_7.1.e000430.74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01527.x"},{"key":"2025091511540625000_7.1.e000430.75","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307087189"},{"key":"2025091511540625000_7.1.e000430.76","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh586"},{"key":"2025091511540625000_7.1.e000430.77","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60413-5","article-title":"Effect of methotrexate on JAK\/STAT pathway activation in myeloproliferative neoplasms","volume":"385","author":"Thomas","year":"2015","journal-title":"Lancet"},{"key":"2025091511540625000_7.1.e000430.78","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096743"},{"key":"2025091511540625000_7.1.e000430.79","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/JLB.5RU0519-145R","article-title":"Jak inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy","volume":"106","author":"Gremese","year":"2019","journal-title":"J Leukoc Biol"},{"key":"2025091511540625000_7.1.e000430.80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: first targeted biological treatment for systemic lupus erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"key":"2025091511540625000_7.1.e000430.81","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0961203316670731","article-title":"Biological therapies in the treatment of cutaneous lupus erythematosus","volume":"26","author":"Presto","year":"2017","journal-title":"Lupus"},{"key":"2025091511540625000_7.1.e000430.82","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0961203316682097","article-title":"Belimumab for the treatment of recalcitrant cutaneous lupus","volume":"26","author":"Vashisht","year":"2017","journal-title":"Lupus"},{"key":"2025091511540625000_7.1.e000430.83","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106174"},{"key":"2025091511540625000_7.1.e000430.84","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"2025091511540625000_7.1.e000430.85","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.39085","article-title":"Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus","volume":"67","author":"Vital","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025091511540625000_7.1.e000430.86","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jamadermatol.2018.3793","article-title":"Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus","volume":"154","author":"Quelhas da Costa","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025091511540625000_7.1.e000430.87","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600414"},{"key":"2025091511540625000_7.1.e000430.88","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.9.1124"},{"key":"2025091511540625000_7.1.e000430.89","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0222-5"},{"key":"2025091511540625000_7.1.e000430.90","doi-asserted-by":"publisher","DOI":"10.1080\/09546630310018789"},{"key":"2025091511540625000_7.1.e000430.91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10825.x"},{"key":"2025091511540625000_7.1.e000430.92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124466"},{"key":"2025091511540625000_7.1.e000430.93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5743"},{"key":"2025091511540625000_7.1.e000430.94","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2025091511540625000_7.1.e000430.95","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01921"},{"key":"2025091511540625000_7.1.e000430.96","doi-asserted-by":"crossref","unstructured":"Furie R , Werth V , Gaudy A , et al . A Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose, Safety, and Pharmacokinetics Study of CC-220 in Subjects with Systemic LUPUS Erythematosus [abstract]. Arthritis Rheumatol 2017;69.","DOI":"10.1136\/annrheumdis-2017-eular.3546"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2020-000430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T18:54:19Z","timestamp":1757962459000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2020-000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,20]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/lupus-2020-000430"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2020-000430","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}